Cargando…
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of...
Autores principales: | Kowalec, Kaarina, Kingwell, Elaine, Carruthers, Robert, Marrie, Ruth Ann, Bernatsky, Sasha, Traboulsee, Anthony, Ross, Colin J D, Carleton, Bruce, Tremlett, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623385/ https://www.ncbi.nlm.nih.gov/pubmed/28576902 http://dx.doi.org/10.1136/bmjopen-2017-016276 |
Ejemplares similares
-
Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022) -
Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019) -
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)